HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide
0.1.0 - CI Build
HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide, published by Te Aho o Te Kahu, Cancer Control Agency. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7NZ/cca/ and changes regularly. See the Directory of published versions
| Active as of 2026-05-21 |
<CodeSystem xmlns="http://hl7.org/fhir">
<id value="sact-esmo-mcbs-evaluation-form"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: CodeSystem sact-esmo-mcbs-evaluation-form</b></p><a name="sact-esmo-mcbs-evaluation-form"> </a><a name="hcsact-esmo-mcbs-evaluation-form"> </a><p>This code system <code>https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form</code> defines the following codes:</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style="white-space:nowrap">ST-1a<a name="sact-esmo-mcbs-evaluation-form-ST-1a"> </a></td><td>Evaluation Form 1a: For RCTs evaluating new approaches to adjuvant therapy or new potentially curative therapies</td></tr><tr><td style="white-space:nowrap">ST-1b<a name="sact-esmo-mcbs-evaluation-form-ST-1b"> </a></td><td>Evaluation Form 1b: For single arm de-escalation studies in the adjuvant setting</td></tr><tr><td style="white-space:nowrap">ST-2a<a name="sact-esmo-mcbs-evaluation-form-ST-2a"> </a></td><td>Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS</td></tr><tr><td style="white-space:nowrap">ST-2b<a name="sact-esmo-mcbs-evaluation-form-ST-2b"> </a></td><td>Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS</td></tr><tr><td style="white-space:nowrap">ST-2c<a name="sact-esmo-mcbs-evaluation-form-ST-2c"> </a></td><td>Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies</td></tr><tr><td style="white-space:nowrap">ST-3<a name="sact-esmo-mcbs-evaluation-form-ST-3"> </a></td><td>Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR</td></tr><tr><td style="white-space:nowrap">HM-1a<a name="sact-esmo-mcbs-evaluation-form-HM-1a"> </a></td><td>Evaluation Form 1a: For RCTs evaluating new approaches to new potentially curative therapies</td></tr><tr><td style="white-space:nowrap">HM-1b<a name="sact-esmo-mcbs-evaluation-form-HM-1b"> </a></td><td>Evaluation Form 1b: For single arm therapies with curative intent and de-escalation studies</td></tr><tr><td style="white-space:nowrap">HM-2a<a name="sact-esmo-mcbs-evaluation-form-HM-2a"> </a></td><td>Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS</td></tr><tr><td style="white-space:nowrap">HM-2b<a name="sact-esmo-mcbs-evaluation-form-HM-2b"> </a></td><td>Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS</td></tr><tr><td style="white-space:nowrap">HM-2c<a name="sact-esmo-mcbs-evaluation-form-HM-2c"> </a></td><td>Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies</td></tr><tr><td style="white-space:nowrap">HM-3<a name="sact-esmo-mcbs-evaluation-form-HM-3"> </a></td><td>Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR</td></tr></table></div>
</text>
<url
value="https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form"/>
<version value="0.1.0"/>
<name value="EsmoMcbsEvaluationForm"/>
<title value="ESMO-MCBS Evaluation Form"/>
<status value="active"/>
<date value="2026-05-21T02:29:02+00:00"/>
<publisher value="Te Aho o Te Kahu, Cancer Control Agency"/>
<description
value="The evaluation forms used in the ESMO Magnitude of Clinical Benefit Scale"/>
<content value="complete"/>
<count value="12"/>
<concept>
<code value="ST-1a"/>
<display
value="Evaluation Form 1a: For RCTs evaluating new approaches to adjuvant therapy or new potentially curative therapies"/>
</concept>
<concept>
<code value="ST-1b"/>
<display
value="Evaluation Form 1b: For single arm de-escalation studies in the adjuvant setting"/>
</concept>
<concept>
<code value="ST-2a"/>
<display
value="Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS"/>
</concept>
<concept>
<code value="ST-2b"/>
<display
value="Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS"/>
</concept>
<concept>
<code value="ST-2c"/>
<display
value="Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies"/>
</concept>
<concept>
<code value="ST-3"/>
<display
value="Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR"/>
</concept>
<concept>
<code value="HM-1a"/>
<display
value="Evaluation Form 1a: For RCTs evaluating new approaches to new potentially curative therapies"/>
</concept>
<concept>
<code value="HM-1b"/>
<display
value="Evaluation Form 1b: For single arm therapies with curative intent and de-escalation studies"/>
</concept>
<concept>
<code value="HM-2a"/>
<display
value="Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS"/>
</concept>
<concept>
<code value="HM-2b"/>
<display
value="Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS"/>
</concept>
<concept>
<code value="HM-2c"/>
<display
value="Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies"/>
</concept>
<concept>
<code value="HM-3"/>
<display
value="Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR"/>
</concept>
</CodeSystem>